Radretumab

From Wikipedia, the free encyclopedia
Radretumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetfibronectin
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.[1][2][3]

References[edit]

  1. ^ "Radretumab (L19-131I)". Philogen. Archived from the original on 6 November 2017.
  2. ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
  3. ^ Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, Bombardieri E, Grana C, Giovannoni L, Neri D, Menssen HD, Mariani G (June 2012). "Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies". Journal of Nuclear Medicine. 53 (6): 922–7. doi:10.2967/jnumed.111.101006. PMID 22577235. S2CID 26518175.